MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
M

2020 Updates on BRAFV600-Mutant Melanoma: FDA-Approved BRAFi + MEKi Regimens vs. BRAFi Mono - What Are the Long-Term PFS/OS Outcomes?

By MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020 FEATURING Michael Davies
By MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020 FEATURING Michael Davies
0 views
November 19, 2020
Comments 0
Login to view comments. Click here to Login

Recommended

AUTOPLAY
12:46
Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner
24:14
Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher
10:01
AAD 2024 Insights

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

Feat. V. Sondak
11:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, …

Feat. D. Johnson
35:23
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel
25:29
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Insights in Melanoma"

Feat. O. Hamid
18:28
Vanderbilt University Medical Center (VUMC)

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Feat. D. Johnson
22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
03:55
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib …

Feat. A. Hauschild
25:44
Scripps Health

Melanoma in the Molecular Age - Part 1: New Tools for Diagnosis, Pro…

Feat. G. Hosler
24:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu
17:07
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

Melanoma Brain Metastases: Successes, Failures, and Future Opportuni…

Feat. M. Postow
11:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We B…

Feat. P. Corrie
20:16
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Immunotherapy & Beyond - Advances in S…

Feat. H. Tawbi
05:37
Melanoma Bridge 2023

COLUMBUS 7-Year Update: Encorafenib + Binimetinib vs. Vemurafenib or…

Feat. R. Dummer
21:29
14th Annual LA Melanoma Symposium

Clinical Trial Options for Melanoma: New Data and Future Therapies

Feat. R. Sullivan
22:58
Tarek Haykal

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

15:18
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Adopting Cutting-Edge Cell Therapies in Me…

Feat. A. Betof Warner
14:42
Jeff Yorio

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

14:23
Alexander Van Akkooi

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment…